Drug Trial Radar · NCT06456528
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
235
Planned (sponsor's estimate)
Start
Oct 22, 2024
Primary completion
Apr 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.
Conditions
- Cancer Treatment-Induced Thrombocytopenia
Interventions
QL0911Drug
QL0911
QL0911 plus PlaceboDrug
QL0911 plus Placebo
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of treatment responders.Time frame: Randomization up to 80 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Harbin First Hospital
Harbin, China · Recruiting
Nanjing Tianyinshan Hospital
Nanjing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.